10 Oversold Pharma Stocks to Buy According to Analysts

5. Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Year Perf: -32.73%

Analyst Upside: 83.29%

Number of Hedge Fund Holders: 40

Amicus Therapeutics, Inc. (NASDAQ:FOLD) is a biotech company that discovers, develops, and delivers medicines to treat metabolic diseases. Its product portfolio includes the first and only approved oral precision medicine to treat Fabry disease, a clinical-stage treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio.

Amicus Therapeutics, Inc. (NASDAQ:FOLD) delivered total revenue of $528 million for the full year 2024, reflecting 32% year-over-year growth and 33% on a constant currency basis. Its product, Galafold, a precision medicine that treats Fabry disease, is continuing a robust commercial growth trajectory and delivered $458 million in revenue in fiscal year 2024. This translates to an 18% year-over-year growth, or 19% at constant exchange rates, making it one of the fastest-growing products within the Fabry treatment space. The drug’s continued penetration into the diagnosed untreated population is anticipated to be a major driver of growth in 2025 and beyond as the Fabry market grows with improved diagnosis and medical education.

The company’s global rare diseases capabilities position it to deliver continued revenue growth and increase profitability in 2025 and beyond. Amicus Therapeutics, Inc.’s (NASDAQ:FOLD) growing medicines with long commercial runways, financial strength, and a leverageable global infrastructure further support these objectives.